iShares U.S. Medical Devices ETF Price & Performance (IHI)

Teleflex Incorporated has seen its stock decline by 22% over the past year, underperforming broader markets. The company missed revenue expectations in Q3 2024, with a modest 2.4% growth. Analysts remain cautious, with a consensus "Moderate Buy" rating. Teleflex's fiscal 2024 results, released today, are expected to show modest EPS growth.1

Amid concerns over economic downturns, defensive sectors like healthcare remain attractive. ETFs such as iShares Global Healthcare and Vanguard Consumer Staples offer stability, benefiting from consistent demand for essential services. Investors are advised to consider these options for recession-resistant portfolios, emphasizing sectors less vulnerable to economic volatility.2

The iShares U.S. Medical Devices ETF has struggled to generate active returns, reflecting broader challenges in the medical device sector. Despite its focus on mid-to-large cap firms, the ETF has underperformed, raising questions about its tactical value. Investors are advised to reassess allocations amid these headwinds.3